|
JAPAN'S DAIICHI SANKYO SEES HYPERTENSION DRUG AS MAJOR EARNER.
Publication: AsiaPulse News Publication Date: 28-FEB-07 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2007 Asia Pulse Pty Ltd
TOKYO, Feb 28 Asia Pulse - Daiichi Sankyo Co. (TSE:4568) is positioning its hypertension treatment olmesartan medoxomil as a major earnings source over the next few years, aiming to boost the product's sales by 90 per cent from the estimated fiscal 2006 level to 270 billion yen (US$2.24 billion)...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from AsiaPulse News |
BRIEFING - ASIA TELECOMMUNICATIONS - FEB 28, 2007.
February 28, 2007
|
ASIAN MARKETS - SHARES END BROADLY LOWER - FEB 28, 2007.
February 28, 2007
|
BRIEFING - ASIA MINING - FEB 28, 2007.
February 28, 2007
|
BRIEFING - ASIA ECONOMIC NEWS - FEB 28, 2007.
February 28, 2007
|
BRIEFING - ASIA BANKING - FEB 28, 2007.
February 28, 2007
|
|
| Find companies classified under Pharmaceutical preparations |
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
